Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May-Jun;14(3):339-341.
doi: 10.1016/j.jobcr.2024.04.006. Epub 2024 Apr 22.

High-dose pulsed hyaluronidase for managing nasal skin necrosis following hyaluronic acid treatment in nasolabial folds: A case report

Marcelo Germani  1 , Panmella Alegria  2 , Gabriela Giro  1 , Victor R M Munoz-Lora  1   3
Affiliations

High-dose pulsed hyaluronidase for managing nasal skin necrosis following hyaluronic acid treatment in nasolabial folds: A case report

Marcelo Germani et al. J Oral Biol Craniofac Res. 2024 May-Jun.

Erratum in

Abstract

The growing popularity of soft tissue filler injections has brought attention to the associated risks, particularly vascular complications, and their treatments. This case report focuses on a 34-year-old female who developed nasal skin necrosis following hyaluronic acid (HA) filler injection for nasolabial fold (NLF) enhancement. Despite the careful procedure, complications emerged rapidly, emphasizing the critical importance of prompt diagnosis and intervention. A total of 10,000 turbidity reducing units (TRU) of hyaluronidase (HSE) were administered in a high-dose pulsed manner, alongside hyperbaric oxygen therapy. The patient experienced a gradual but significant improvement over 60 days. This case underscores the need for constant vigilance in aesthetic medicine and the potential consequences of even minute HA amounts, exceeding zero, in causing severe vascular events.

Keywords: Hyaluronic acid; Ischemia; Necrosis.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflict of interests.

Figures

Image 1
Graphical abstract
Fig. 1
Fig. 1
Assessment of the patient 12 h post-treatment in a A) frontal and B) left lateral view. Changes in skin color on the left side of the face and lips can be observed.
Fig. 2
Fig. 2
Assessment of the patient's nose from a A) lateral, B) inferior and C) frontal view 6 days post-treatment. The nose exhibited characteristics of advanced scarring.
Fig. 3
Fig. 3
Assessment of the patient's nose from a A) lateral, B) inferior and C) frontal view 60 days post-treatment. The nose exhibited characteristics of recovery.
See this image and copyright information in PMC

References

    1. Xiong M., Chen C., Sereda Y., Garibyan L., Avram M., Lee K.C. Retrospective analysis of the MAUDE database on dermal filler complications from 2014–2020. J Am Acad Dermatol. 2022;87(5):1158–1160. - PubMed
    1. Murray G., Convery C., Walker L., Davies E. Guideline for the safe use of hyaluronidase in aesthetic medicine, including modified high-dose protocol. J Clin Aesthet Dermatol. 2021;14(8):E69–E75. - PMC - PubMed
    1. Quezada-Gaón N., Wortsman X. Ultrasound-guided hyaluronidase injection in cosmetic complications. J Eur Acad Dermatol Venereol. 2016;30(10):e39–e40. - PubMed
    1. Cohen J.L., Biesman B.S., Dayan S.H., et al. Treatment of hyaluronic acid filler–induced impending necrosis with hyaluronidase: consensus recommendations. Aesthetic Surg J. 2015;35(7):844–849. - PubMed
    1. DeLorenzi C. New high dose pulsed hyaluronidase protocol for hyaluronic acid filler vascular adverse events. Aesthetic Surg J. 2017;37(7):814–825. - PubMed